In the News
March 19, 2014
Avella Specialty Pharmacy on Tuesday announced that it has registered with the Food and Drug Administration as an outsourcing facility for sterile compounding as outlined in the recently enacted Drug Quality and Security Act. Outsource facilities must consent to greater federal oversight including more frequent inspections and are required to demonstrate their adherence to specific “good manufacturing practices,” Avella noted.
February 24, 2014
Health care providers have long recognized nonadherence as a major barrier to positive patient health outcomes and a significant cause of increased health care costs. Nonadherence dates back to Hippocrates, who advised physicians “to keep watch for that fault in patients which makes them lie about the things prescribed.” Robert Koch, the 1905 Nobel Prize winner for his discovery of the bacterium that causes tuberculosis, described noncompliant patients as “vicious consumptives, careless and/or irresponsible.” Perhaps the most succinct and straightforward description of nonadherence is then-Surgeon General of the United States Dr. C. Everett Koop’s famous quote of the 1980s, “Drugs don’t work in patients who don’t take them.”
February 21, 2014
As part of a study conducted with the University of Arizona, Avella Specialty Pharmacy proved the value of pharmacist intervention in improving patient outcomes, at least in renal transplant patients, to the tune of $27,852 per month, Avella announced Thursday. The study found that participants in the intervention group had a statistically significant improvement in adherence rates over patients in the control group who did not have a contract or receive support to ensure adherence to their monthly medication therapy. The study also found that patients who complied with their medication regimens had fewer inpatient and outpatient visits and were 78% more likely not to be hospitalized, hence the monthly savings.
February 20, 2014
Accountable care organizations (ACOs)—the trending new delivery model in which care is coordinated to achieve both cost efficiencies and improved quality—offer a rich new field of possible partnership opportunities for specialty pharmacy, suggested experts participating in the first of a series of webinars on ACOs and specialty pharmacy cosponsored by Avalere Health, Armada Health Care and the Specialty Pharmacy Association of America (SPAARx).
February 20, 2014
Avella Specialty Pharmacy, Biologics, Diplomat Specialty Pharmacy, Onco360 and Total Life Care (TLC) are the exclusive distributors of ibrutinib, the once-daily oral Bruton tyrosine kinase (BTK) inhibitor recently approved for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
February 14, 2014
Five specialty pharmacies, including Avella and Diplomat, are part of limited distribution network
January 17, 2014
Chief Executive magazine today recognized the Mid-Market Elite — 100 exceptional companies with revenue between $10 million and $1 billion. “The Middle Market often gets overlooked, in the shadows of big corporations and small business,” said J.P. Donlon, editor in chief of Chief Executive magazine. “While accounting for just 3% of U.S. companies, the Middle Market is responsible for 1/3 of all jobs and 36% of U.S. payrolls. The Mid-Market Elite represent the best within this critical sector.” Mid-Market Elite winners demonstrate at least one of the following characteristics: superior growth, a track record of innovation, an exceptional corporate culture, charismatic leadership, and a compelling business model.
January 10, 2014
Avella Provides Guidance on Factors to Consider when Selecting a Specialty Pharmacy for Hepatitis C Patients
Avella Specialty Pharmacy recently released a white paper to guide the selection of the appropriate specialty pharmacy for hepatitis C patients. Avella’s “Guide to Selecting the Appropriate Specialty Pharmacy for Patients with Hepatitis C” highlights the key factors to consider when choosing a specialty pharmacy for the over five million Americans infected with the virus
January 06, 2014
Adherence with Oral Oncology Medications: Implications for Nurses
December 24, 2013
Prostate cancer (PrCa) is among the most commonly diagnosed cancers, second to only skin cancer, and is also the secondleading cause of cancer-related deaths among males in the developed world.1 Although the frequency of PrCa diagnoses experienced a 2% decline between 2000 and 2010, it is estimated that there will be 238,590 diagnoses in 2013, with 29,270 deaths related to PrCa. Approximately 1 in 6 males will be diagnosed with PrCa in his lifetime, and 1 in 36 men will die of the disease. The median age at initial diagnosis is 66 years, with an average age of mortality of 80 years.
From the Avella Blog
April 22, 2014
Manufacturers can become overwhelmed with specialty pharmacy data complexity. Oftentimes, the incompleteness can make the data difficult to use. The most successful approach to data analytics is based on aligning a manufacturer’s specialty pharmacy data requirements with its business needs, therapy category and pharmacy capabilities. This provides more efficient data quality management and more effective business utilization. With the increased supply of information, data analytics should be a ...